title: Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen.
abstract: OBJECTIVE
  To determine the percentage of localized and potentially curable prostate cancers diagnosed at follow-up screening visits compared with the first screening visit.
  
  
  METHODS
  Within the context of a prospective screening study performed in randomly chosen men aged between 45 and 80 years, up to 6-year follow-up screening visits have been performed with serum prostate-specific antigen (PSA) measurement and digital rectal examination (DRE) followed by transrectal ultrasonography of the prostate when PSA or DRE is abnormal.
  
  
  RESULTS
  Of the 117 prostate cancers diagnosed at 14,554 annual follow-up visits, only 1 cancer (0.9%) was metastatic compared with 8% (26/322) at 8029 first visits. Moreover, 97% of the cancers detected at follow-up visits could be identified by PSA alone compared with 86% at first visit. The incidence of 0.8% per year during 15 years of screening between the ages of 55 and 70 years would diagnose localized prostate cancer in 12% of the population, a value not too different from the 10% diagnosed with prostate cancer during life-time in the absence of screening.
  
  
  CONCLUSIONS
  The present data show that annual screening with PSA diagnoses clinically localized prostate cancer in more than 95% of cases, thus almost completely eliminating the diagnosis of metastatic prostate cancer. Moreover, the number of prostate cancers diagnosed is not significantly increased by screening.
authors.affiliation: Prostate Cancer Clinical Research Unit, CHUL Research Center, Québec, Canada.
authors.forename: F
authors.initials: F
authors.lastname: Labrie
authors.forename: B
authors.initials: B
authors.lastname: Candas
authors.forename: L
authors.initials: L
authors.lastname: Cusan
authors.forename: J L
authors.initials: JL
authors.lastname: Gomez
authors.forename: P
authors.initials: P
authors.lastname: Diamond
authors.forename: R
authors.initials: R
authors.lastname: Suburu
authors.forename: M
authors.initials: M
authors.lastname: Lemay
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000379:methods / Q000706:statistics & numerical data; D008875:Middle Aged; D009367:Neoplasm Staging; D010808:Physical Examination; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000517:prevention & control; D011792:Quebec; D012007:Rectum; D011795:Surveys and Questionnaires
chemical_list: D017430:Prostate-Specific Antigen